

SUPPLEMENTARY INFORMATION

Table s1. Sensitivity and specificity and cutoff of significant genes in survival analysis

| Gene | Sensitivity | Specificity | Cutoff |
|----------------|--------------------|--------------------|---------------|
| <i>ALDH1A1</i> | 79.2% | 70.0% | 7.74 |
| <i>CXCL9</i> | 83.3% | 71.9% | 10.34 |
| <i>FGF1</i> | 73.6% | 76.7% | 6.12 |
| <i>FGL2</i> | 83.3% | 77.1% | 8.21 |
| <i>GRIN2A</i> | 72.7% | 75.4% | 4.46 |
| <i>KCNB1</i> | 70.0% | 76.0% | 3.96 |
| <i>SNAI1</i> | 81.8% | 72.8% | 7.46 |
| <i>VEGFA</i> | 77.0% | 77.0% | 9.19 |

Table s2. Differential analysis between pCR and RD in both treatment arms

| Gene | Fold-change | Expression | p-value |
|----------------|--------------------|-------------------|----------------|
| <i>FOXC2</i> | -3.18 | downregulated | 0.001 |
| <i>KCNB1</i> | -2.66 | downregulated | 0.008 |
| <i>ZBTB16</i> | -2.59 | downregulated | 0.002 |
| <i>TFF1</i> | -2.52 | downregulated | 0.003 |
| <i>GRIN2A</i> | -2.30 | downregulated | 0.009 |
| <i>C5orf38</i> | -2.08 | downregulated | 0.007 |
| <i>VEGFA</i> | -2.06 | downregulated | 0.004 |
| <i>HAS1</i> | -1.96 | downregulated | 0.007 |
| <i>INHBA</i> | -1.92 | downregulated | 0.006 |
| <i>PGR</i> | -1.97 | downregulated | 0.008 |
| <i>PLA2G4F</i> | -1.96 | downregulated | 0.009 |
| <i>BNIP3</i> | -1.85 | downregulated | 0.005 |
| <i>FGF1</i> | -1.89 | downregulated | 0.005 |
| <i>DLL4</i> | -1.78 | downregulated | 0.003 |
| <i>SNAI1</i> | -1.76 | downregulated | 0.003 |
| <i>ADCY9</i> | -1.64 | downregulated | 0.005 |
| <i>RAD52</i> | -1.51 | downregulated | 0.008 |
| <i>HEMK1</i> | -1.43 | downregulated | 0.001 |
| <i>HDAC2</i> | 1.54 | upregulated | 0.004 |
| <i>MCM2</i> | 1.63 | upregulated | 0.004 |
| <i>ALDH1A1</i> | 2.11 | upregulated | 0.005 |
| <i>FGL2</i> | 2.27 | upregulated | 0.006 |
| <i>CXADR</i> | 2.29 | upregulated | 0.005 |
| <i>CXCL9</i> | 4.26 | upregulated | 0.008 |

Figure s1. Design of the NACATRINE clinical trial.




Figure s2. Consort of the exploratory analysis of the NACATRINE trial

